CARF: An emerging regulator of p53 tumor suppressor and senescence pathway

Mechanisms of Ageing and Development

Volumn 130, Issue 1-2, 2009, Pages 18-23

  Cheung, Caroline T Y ^a   Hasan, Md Kamrul ^b   Widodo, Nashi ^a   Kaul, Sunil C ^a   Wadhwa, Renu ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

ARF; Carcinogenesis; CARF; p53; Senescence

Indexed keywords

ARF PROTEIN; CALVASCULIN; CDKN2 PROTEIN; COLLABORATOR OF ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; INK4A PROTEIN; PROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CARCINOGENESIS; CELL AGING; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL PROTECTION; CELL REGENERATION; CELL STRESS; DEFENSE MECHANISM; FUNCTIONAL PROTEOMICS; GENE INDUCTION; HUMAN; LIFESPAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATOR GENE; REGULATORY MECHANISM; SENESCENCE;

AGED; AGING; AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149343971     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2008.05.002     Document Type: Article

References (92)

1. Ashton-Prolla P., Bakos L., Junqueira Jr. G., Giugliani R., Azevedo S.J., and Hogg D. Clinical and molecular characterization of patients at risk for hereditary melanoma in southern Brazil. J. Invest. Dermatol. 128 (2008) 421-425
2. Bartek J., Bartkova J., and Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26 (2007) 7773-7779
3. Bean G.R., Bryson A.D., Pilie P.G., Goldenberg V., Baker Jr. J.C., Ibarra C., Brander D.M., Paisie C., Case N.R., Gauthier M., Reynolds P.A., Dietze E., Ostrander J., Scott V., Wilke L.G., Yee L., Kimler B.F., Fabian C.J., Zalles C.M., Broadwater G., Tlsty T.D., and Seewaldt V.L. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin. Cancer Res. 13 (2007) 6834-6841
4. Belaud-Rotureau M.A., Marietta V., Vergier B., Mainhaguiet G., Turmo M., Idrissi Y., Ferrer J., Beylot-Barry M., Dubus P., and Merlio J.P. Inactivation of p16 (INK4a)/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. Virchows. Arch. 452 (2008) 607-620
5. Benanti J.A., Williams D.K., Robinson K.L., Ozer H.L., and Galloway D.A. Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1. Mol. Cell. Biol. 22 (2002) 7385-7397
6. Benanti J.A., Wang M.L., Myers H.E., Robinson K.L., Grandori C., and Galloway D.A. Epigenetic down-regulation of ARF expression is a selection step in immortalization of human fibroblasts by c-Myc. Mol. Cancer Res. 5 (2007) 1181-1189
7. Blackburn E.H. Switching and signaling at the telomere. Cell 106 (2001) 661-673
8. Cip1/WAF1 gene in normal diploid human fibroblasts. Science 277 (1997) 831-834
9. Bryan T.M., Englezou A., Dalla-Pozza L., Dunham M.A., and Reddel R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3 (1997) 1271-1274
10. Buchmann A.M., Swaminathan S., and Thimmapaya B. Regulation of cellular genes in a chromosomal context by the retinoblastoma tumor suppressor protein. Mol. Cell. Biol. 18 (1998) 4565-4576
11. Campbell K.J., Rocha S., and Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell 13 (2004) 853-865
12. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120 (2005) 513-522
13. Chen J.H., Stoeber K., Kingsbury S., Ozanne S.E., Williams G.H., and Hales C.N. Loss of proliferative capacity and induction of senescence in oxidatively stressed human fibroblasts. J. Biol. Chem. 279 (2004) 49439-49446
14. Chen Q.M., Tu V.C., Catania J., Burton M., Toussaint O., and Dilley T. Involvement of Rb family proteins, focal adhesion proteins and protein synthesis in senescent morphogenesis induced by hydrogen peroxide. J. Cell. Sci. 113 Pt 22 (2000) 4087-4097
15. Chkhotua A.B., Gabusi E., Altimari A., D'Errico A., Yakubovich M., Vienken J., Stefoni S., Chieco P., Yussim A., and Grigioni W.F. Increased expression of p16(INK4a) and p27(Kip1) cyclin-dependent kinase inhibitor genes in aging human kidney and chronic allograft nephropathy. Am. J. Kidney Dis. 41 (2003) 1303-1313
16. Conconi M., Szweda L.I., Levine R.L., Stadtman E.R., and Friguet B. Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90. Arch. Biochem. Biophys. 331 (1996) 232-240
17. Coppe J.P., Kauser K., Campisi J., and Beausejour C.M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem. 281 (2006) 29568-29574
18. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., and Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (2003) 194-198
19. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9363-9367
20. Dimri G.P., Itahana K., Acosta M., and Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol. Cell. Biol. 20 (2000) 273-285
21. Eymin B., Karayan L., Seite P., Brambilla C., Brambilla E., Larsen C.J., and Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20 (2001) 1033-1041
22. Fatyol K., and Szalay A.A. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J. Biol. Chem. 276 (2001) 28421-28429
23. Federico A., Morgillo F., Tuccillo C., Ciardiello F., and Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 121 (2007) 2381-2386
24. Garcia-Cao I., Garcia-Cao M., Martin-Caballero J., Criado L.M., Klatt P., Flores J.M., Weill J.C., Blasco M.A., and Serrano M. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21 (2002) 6225-6235
25. Gasparini P., Sozzi G., and Pierotti M.A. The role of chromosomal alterations in human cancer development. J. Cell. Biochem. 102 (2007) 320-331
26. Ginalski K., Elofsson A., Fischer D., and Rychlewski L. 3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics 19 (2003) 1015-1018
27. Harley C.B., Futcher A.B., and Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 345 (1990) 458-460
28. Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., and Kaul S.C. Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Biochem. J. 380 (2004) 605-610
29. Hasan M.K., Yaguchi T., Sugihara T., Kumar P.K., Taira K., Reddel R.R., Kaul S.C., and Wadhwa R. CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53. J. Biol. Chem. 277 (2002) 37765-37770
30. Hasan M.K., Wadhwa R., and Kaul S.C. CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-suppressor pathway. Ann. NY Acad. Sci. 1100 (2007) 312-315
31. Hasan M.K., Yaguchi T., Harada J.I., Hirano T., Wadhwa R., and Kaul S.C. CARF (collaborator of ARF) interacts with HDM2: Evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway. Int. J. Oncol. 32 (2008) 663-671
32. Hayflick L., and Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell. Res. 25 (1961) 585-621
33. Honda R., and Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18 (1999) 22-27
34. Hulo N., Bairoch A., Bulliard V., Cerutti L., Cuche B.A., de Castro E., Lachaize C., Langendijk-Genevaux P.S., and Sigrist C.J. The 20 years of PROSITE. Nucleic Acids Res. 36 Database issue (2008) D245-D249
35. Jackson M.W., Lindstrom M.S., and Berberich S.J. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J. Biol. Chem. 276 (2001) 25336-25341
36. Johnson T.M., Meade K., Pathak N., Marques M.R., and Attardi L.D. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 1215-1220
37. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., and Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91 (1997) 649-659
38. Kamoshida S., Matsuoka H., Shiogama K., Matsuyama A., Shimomura R., Inada K., Maruta M., and Tsutsumi Y. Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil. Pathol. Int. 54 (2004) 564-575
39. Karayan L., Riou J.F., Seite P., Migeon J., Cantereau A., and Larsen C.J. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 20 (2001) 836-848
40. Kim W.Y., and Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 127 (2006) 265-275
41. Kohno T., Yamada Y., Tawara M., Takasaki Y., Kamihira S., Tomonaga M., and Matsuyama T. Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma. Leuk. Res. 31 (2007) 1625-1632
42. Krishnamurthy J., Torrice C., Ramsey M.R., Kovalev G.I., Al-Regaiey K., Su L., and Sharpless N.E. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114 (2004) 1299-1307
43. Krokan H.E., Kavli B., and Slupphaug G. Novel aspects of macromolecular repair and relationship to human disease. J. Mol. Med. 82 (2004) 280-297
44. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
45. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., and Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9 (1989) 3982-3991
46. Liu Y., Snow B.E., Hande M.P., Yeung D., Erdmann N.J., Wakeham A., Itie A., Siderovski D.P., Lansdorp P.M., Robinson M.O., and Harrington L. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr. Biol. 10 (2000) 1459-1462
47. Maier B., Gluba W., Bernier B., Turner T., Mohammad K., Guise T., Sutherland A., Thorner M., and Scrable H. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18 (2004) 306-319
48. Martelli F., Hamilton T., Silver D.P., Sharpless N.E., Bardeesy N., Rokas M., DePinho R.A., Livingston D.M., and Grossman S.R. p19ARF targets certain E2F species for degradation. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4455-4460
49. Matheu A., Pantoja C., Efeyan A., Criado L.M., Martin-Caballero J., Flores J.M., Klatt P., and Serrano M. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev. 18 (2004) 2736-2746
50. Matheu A., Maraver A., Klatt P., Flores I., Garcia-Cao I., Borras C., Flores J.M., Vina J., Blasco M.A., and Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448 (2007) 375-379
51. Menendez S., Khan Z., Coomber D.W., Lane D.P., Higgins M., Koufali M.M., and Lain S. Oligomerization of the human ARF tumor suppressor and its response to oxidative stress. J. Biol. Chem. 278 (2003) 18720-18729
52. Mitsui Y., and Schneider E.L. Relationship between cell replication and volume in senescent human diploid fibroblasts. Mech. Ageing Dev. 5 (1976) 45-56
53. Oguro H., Iwama A., Morita Y., Kamijo T., van Lohuizen M., and Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J. Exp. Med. 203 (2006) 2247-2253
54. Papazoglu C., and Mills A.A. p53: at the crossroad between cancer and ageing. J. Pathol. 211 (2007) 124-133
55. Parrinello S., Coppe J.P., Krtolica A., and Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell. Sci. 118 (2005) 485-496
56. Pauklin S., Kristjuhan A., Maimets T., and Jaks V. ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. Biochem. Biophys. Res. Commun. 334 (2005) 386-394
57. Pollice A., Nasti V., Ronca R., Vivo M., Lo Iacono M., Calogero R., Calabro V., and La Mantia G. Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J. Biol. Chem. 279 (2004) 6345-6353
58. Qi Y., Gregory M.A., Li Z., Brousal J.P., West K., and Hann S.R. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431 (2004) 712-717
59. Quelle D.E., Zindy F., Ashmun R.A., and Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83 (1995) 993-1000
60. Randle D.H., Zindy F., Sherr C.J., and Roussel M.F. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9654-9659
61. Rizos H., Diefenbach E., Badhwar P., Woodruff S., Becker T.M., Rooney R.J., and Kefford R.F. Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition. J. Biol. Chem. 278 (2003) 4981-4989
62. Sailasree R., Abhilash A., Sathyan K.M., Nalinakumari K.R., Thomas S., and Kannan S. Differential Roles of p16INK4A and p14ARF Genes in Prognosis of Oral Carcinoma. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 414-420
63. Saporita A.J., Maggi Jr. L.B., Apicelli A.J., and Weber J.D. Therapeutic targets in the ARF tumor suppressor pathway. Curr. Med. Chem. 14 (2007) 1815-1827
64. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., and DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85 (1996) 27-37
65. Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
66. Serrano M., and Blasco M.A. Cancer and ageing: convergent and divergent mechanisms. Nat. Rev. Mol. Cell. Biol. 8 (2007) 715-722
67. Sharpless N.E., Ramsey M.R., Balasubramanian P., Castrillon D.H., and DePinho R.A. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 23 (2004) 379-385
68. Shay J.W., Pereira-Smith O.M., and Wright W.E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell. Res. 196 (1991) 33-39
69. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6 (2006) 663-673
70. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3 (2003) 155-168
71. Sitte N., Merker K., Von Zglinicki T., Grune T., and Davies K.J. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I-effects of proliferative senescence. FASEB J. 14 (2000) 2495-2502
72. Smogorzewska A., and de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21 (2002) 4338-4348
73. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., and Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17 (1998) 5001-5014
74. Sugihara T., Kaul S.C., Kato J., Reddel R.R., Nomura H., and Wadhwa R. Pex19p dampens the p19ARF-p53-p21WAF1 tumor suppressor pathway. J. Biol. Chem. 276 (2001) 18649-18652
75. Tao W., and Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6937-6941
76. Tsutsui T., Kumakura S., Yamamoto A., Kanai H., Tamura Y., Kato T., Anpo M., Tahara H., and Barrett J.C. Association of p16(INK4a) and pRb inactivation with immortalization of human cells. Carcinogenesis 23 (2002) 2111-2117
77. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., Hee Park S., Thompson T., Karsenty G., Bradley A., and Donehower L.A. p53 mutant mice that display early ageing-associated phenotypes. Nature 415 (2002) 45-53
78. Venkitaraman A.R. Chromosomal instability in cancer: causality and interdependence. Cell. Cycle 6 (2007) 2341-2343
79. Vivo M., Calogero R.A., Sansone F., Calabro V., Parisi T., Borrelli L., Saviozzi S., and La Mantia G. The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J. Biol. Chem. 276 (2001) 14161-14169
80. von Zglinicki T., Saretzki G., Ladhoff J., d'Adda di Fagagna F., and Jackson S.P. Human cell senescence as a DNA damage response. Mech. Ageing Dev. 126 (2005) 111-117
81. Wadhwa R., Sugihara T., Hasan M.K., Taira K., Reddel R.R., and Kaul S.C. A major functional difference between the mouse and human ARF tumor suppressor proteins. J. Biol. Chem. 277 (2002) 36665-36670
82. Wadhwa R., Sugihara T., Hasan M.K., Duncan E.L., Taira K., and Kaul S.C. A novel putative collaborator of p19ARF. Exp. Gerontol. 38 (2003) 245-252
83. Wang X.Q., Gabrielli B.G., Milligan A., Dickinson J.L., Antalis T.M., and Ellem K.A. Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay. Cancer Res. 56 (1996) 2510-2514
84. Wang Y., Schulte B.A., LaRue A.C., Ogawa M., and Zhou D. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 107 (2006) 358-366
85. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., and Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell. Biol. 1 (1999) 20-26
86. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., Sherr C.J., and Zambetti G.P. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 14 (2000) 2358-2365
87. Woods Y.L., Xirodimas D.P., Prescott A.R., Sparks A., Lane D.P., and Saville M.K. p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase. J. Biol. Chem. 279 (2004) 50157-50166
88. Wright W.E., and Shay J.W. Historical claims and current interpretations of replicative aging. Nat. Biotechnol. 20 (2002) 682-688
89. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
90. Zhao L., Samuels T., Winckler S., Korgaonkar C., Tompkins V., Horne M.C., and Quelle D.E. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol. Cancer Res. 1 (2003) 195-206
91. Zhang Y., and Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3 (1999) 579-591
92. Zindy F., Williams R.T., Baudino T.A., Rehg J.E., Skapek S.X., Cleveland J.L., Roussel M.F., and Sherr C.J. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15930-15935